For a healthier world

What does Quercis Pharma do?

Quercis Pharma AG is leveraging its novel antithrombotic platform to deliver innovative, safe, and broadly accessible treatments to patients with potentially life-threatening conditions.

Our focus is on prevention of venous thrombosis and pulmonary embolism in high risk cancer patients with our drug candidate ISQ950AN, containing our patented Isoquercetin formulation.

Image Description

The safety of our investigational drug has been proven in various studies, with no serious side effects having been identified, in particular our drug shows no increased bleeding risk.

Image Description

A clinical Phase 2 study has shown that ISQ950AN reduced hypercoagulability in cancer patients at high risk for thrombosis with an improved benefit/risk ratio.

Image Description

Our novel pathway is based on a new mechanism of action, in order to arrest and/or reverse platelet aggregation with a profile that conveys vastly lowered bleeding risk compared to current standard of care.

Image Description

We control both the raw material production and the Active Performance Ingredient (API) manufacture for our investigational drug ISQ950AN through our subsidiary Quercegen Pharmaceuticals LLC., making Quercis the world’s biggest manufacturer and distributor of pure Quercetin that is GRAS (“Generally Recognized As Safe” by FDA).

Image Description

The humanitarian aspect of the Company is to look at global disease dangers in less privileged populations and to work with Governments and NGOs to improve healthcare in countries where they find it difficult to pay for development or production of new drugs to combat critical health threats (such as Ebola and Zika Viruses).

Image Description



Quercegen Pharmaceuticals LLC is formed and enters into many research collaborations with DARPA, AFFRI, CFD (US Army), and multiple top universities globally.

Merck KGaA’s Natural Products business, farms and manufacturing plants were bought and integrated.

Purchasing of a stake in Nutravail, a supplement producer with an R&D facility.

Research into combinations of flavonoids and flavonoids with vitamins.


Ten years of research and development focusing on flavonoids and naturally occurring small molecule formulations.

Collaborations with leading institutions, universities and hospitals around the world.


Quercis Pharma AG is formed.

Quercegen Companies’ manufacturing and pharmaceutical assets integrated to Quercis.

Quercis took ownership of FDA IND of the successfully completed Phase 2 trial in VTE prevention in advanced metastatic cancers. All clinical programs and patents transferred to Quercis.

Successful End-of Phase 2 / Phase 3 protocol discussion with FDA.

Results from Phase 2 study on VTE prevention in cancer – the author’s take

Drug Development


Isoquercetin (ISQ950AN) patented formulation

Isoquercetin prevents platelet activation and initiation of the thrombotic cascade.

Over 20’000 publications referencing Isoquercetin and Quercetin in multiple indications

Safety profile of our main investigational drug is well established; does not cause bleeding – a significant advantage over Heparins and Direct Oral Anticoagulants

Image Description
Lead indication: VTE prevention in cancer

Venous thromboembolism (VTE), which includes deep vein thrombosis (DVT) and pulmonary embolism (PE), is an important cause of morbidity and mortality among patients with cancer.

Besides increased risk of VTE, advanced cancer patients have a significantly increased bleeding risk.

Major bleeds are a side effect of today’s anti-coagulants (ACs).

As a result, Venous thromboembolism (VTE) prevention remains limited for advanced cancer patients, despite these patients being at a high risk of VTE.

Currently, anticoagulant use is not recommended prophylactically to cancer patients due to significantly increased bleeding risk.

Quercis’ drug is expected to prevent VTE effectively without increased risk of bleeding.

Image Description
Other high-priority indication: COVID-19

Evidence of Quercis’ drug candidate ISQ950AN being effective against a variety of virus infections (COVID-19, Influenza, HCV, hRSV, Rhinovirus, Ebola, HIV, etc).

Most patients with severe COVID-19 experience high levels of the D-dimer biomarker that underline higher risks of various forms of thrombosis particularly in the lungs. ISQ950AN’s capacity to inhibit thrombosis and decrease D-dimers in other context may prevent the life-threatening thrombotic events seen in these patients.

Various governments have requested collaboration and several Phase III trials are being prepared

Image Description
Other advanced indications (Phase II trials)

Treatment of Chronic Obstructive Pulmonary Disease (COPD)

Treatment of Sickle Cell Disease (SCD)

Treatment of Amyotrophic Lateral Sclerosis (ALS) – clearly orphan disease

Treatment of thrombi

Reduction of tumor metastasis

Prevention and treatment of viral diseases


Scientific Advisory Board


Operational Team
Ilias joined Quercis Pharma AG in 2019 coming from Cevian Capital, Europe’s largest active ownership fund. For the last twelve years he was a Partner and Managing Director at Cevian. Before he had been with McKinsey and Company for seven years. Ilias holds a Master of Science in Business Engineering from ETH Zurich, a Ph.D. in Corporate Finance from the University of Zurich, and a Certificate in Corporate Governance form INSEAD.
Jeffrey is the Primary Investigator of various of Quercis’ clinical trials, in particular for the lead indication of VTE prevention in cancer. He is a Professor of Medicine at Harvard Medical School and Chief of the Section of Benign Hematology at Beth Israel Deaconess Medical Center. His research is focused on novel risk factors and therapeutic approaches to thrombotic diseases with an emphasis on cancer associated thrombosis.
Thomas founded Quercis and its predecessor company Quercegen Pharmaceuticals, which acquired the Merck Natural Products Division 2009. He has been the driving force behind the successful development of Quercis’ drug development program. Thomas is a serial entrepreneur, scientist and successful inventor, who has registered multiple drug patents and trademarks. He is the world’s leading expert on naturally occurring small molecules as disease prevention agents with a specific emphasis on Flavonoids.
Dr Jean-Pierre Bizzari is a world-renowned oncology expert with over 35 years of broad experience in oncology drug development. He is former CMO of Celgene where he presided over the registration of drugs including Abraxane, the frontline therapy for pancreatic cancer, Revilimid, Vidaza, Istodax, and Taxotere. He is Professor emeritus of Pathology at Harvard Medical School, and he was a member of National Institute of Health (NIH) expert panels, and of the medical Board of the American Asthma Foundation in the USA. In addition, he was Chairman of Celgene's hematology oncology development committee and a member of its management committee.
Philippe is the former French Minister for Health, a former member of the European Parliament and a United Nations official who has served as Under-Secretary-General of the United Nations and chairman of UNITAID. He studied medicine in Toulouse, became Professor of Medicine at Toulouse Sciences University in 1988, and since 2016, he has also been a visiting Professor at the Harvard T.H. Chan School of Public Health.
Stefan has over 35 years experience in the pharmaceutical and biotech industry. Most recently he was Chief Medical Officer and Head of R&D at Vifor Pharma with responsibility for preclinical and clinical R&D, regulatory and medical affairs as well as drug safety. Prior to that he was Head of Clinical Research at Novartis OTC and worked 20 years at Bayer in R&D. He is the founder of two start-up companies in the oncology area. Stefan holds a Medical Doctor’s degree from the University of Düsseldorf, Germany.
Mukesh has been involved in more than 100 multi-national clinical trials, and has made hundreds of submissions to the US FDA, EMA, and regulators in more than 40 countries. He has led numerous teams for development of pharmaceutical, biotech and medical device products all the way from early stage development to commercial markets. He authors a popular Weekly Newsletter on FDA related issues read by more than 100,000 readers worldwide.

Raw material production and Active Performance Ingredient manufacture